Lyell Immunopharma (NASDAQ:LYEL) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Lyell Immunopharma from “sell” to “hold,” while broader analyst sentiment remains mixed with an overall average rating of “Moderate Buy” and a $43.00 average price target.
• The stock was down 3.6% and opened at $19.33, below both its 50-day moving average of $22.19 and 200-day moving average of $23.52. It remains far under its 12-month high of $45.00.
• Lyell reported no revenue in its latest quarter and EPS of -$1.10, matching expectations, while analysts still forecast a full-year loss of -$10.45 per share.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Sunday.

LYEL has been the topic of a number of other research reports. Citizens Jmp began coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They set a "market outperform" rating and a $34.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Needham & Company LLC reissued a "buy" rating and set a $44.00 price objective on shares of Lyell Immunopharma in a report on Thursday. Zacks Research lowered Lyell Immunopharma from a "hold" rating to a "strong sell" rating in a research report on Tuesday, April 7th. Finally, Robert W. Baird set a $49.00 target price on Lyell Immunopharma and gave the stock an "outperform" rating in a report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $43.00.

Lyell Immunopharma Trading Down 3.6%

LYEL stock opened at $19.33 on Friday. The firm has a 50-day moving average price of $22.19 and a 200-day moving average price of $23.52. Lyell Immunopharma has a 12 month low of $7.65 and a 12 month high of $45.00. The stock has a market capitalization of $450.97 million, a P/E ratio of -1.40 and a beta of -0.05.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.10). The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 84.36%. As a group, equities analysts predict that Lyell Immunopharma will post -10.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Stephen J. Hill sold 1,236 shares of the business's stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the sale, the chief operating officer owned 17,795 shares of the company's stock, valued at $416,225.05. The trade was a 6.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gary K. Lee sold 1,671 shares of the stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $39,084.69. Following the completion of the sale, the insider owned 16,938 shares of the company's stock, valued at $396,179.82. The trade was a 8.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 11,310 shares of company stock valued at $264,285 in the last ninety days. 6.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently made changes to their positions in the stock. Foresite Capital Management V LLC increased its position in Lyell Immunopharma by 17.3% during the 3rd quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company's stock valued at $7,748,000 after purchasing an additional 70,426 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Lyell Immunopharma by 7.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company's stock valued at $2,629,000 after purchasing an additional 5,913 shares in the last quarter. Marshall Wace LLP acquired a new position in Lyell Immunopharma during the 4th quarter worth approximately $2,257,000. State Street Corp raised its position in shares of Lyell Immunopharma by 52.5% during the fourth quarter. State Street Corp now owns 51,472 shares of the company's stock worth $1,584,000 after purchasing an additional 17,720 shares during the period. Finally, Acadian Asset Management LLC raised its holdings in Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the last quarter. Institutional investors own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.